Appointments Jobs About Search Education & Research Clinical Trials Health Information Medical Services

Publications - Michael D . McGoon, M.D.

Back to Research Profile

  1. Badesch DB, McGoon MD, Barst RJ, Tapson VF, Rubin LJ, Wigley FM, Kral KM, Raphiou IH, Crater GD. Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol. J Rheumatol 2009 Oct; 36(10):2244-9. Epub 2009 Sep 01.
    View PubMed
  2. Taichman DB, McGoon MD, Harhay MO, Archer-Chicko C, Sager JS, Murugappan M, Chakinali MM, Palevsky HI, Gallop R. Wide variation in clinicians' assessment of New York Heart Association/World Health Organization functional class in patients with pulmonary arterial hypertension. Mayo Clin Proc 2009 Jul; 84(7):586-92.
    View PubMed
  3. Badesch DB, Champion HC, Sanchez MAG, Hoeper MM, Loyd JE, Manes A, McGoon M, Naeije R, Olschewski H, Oudiz RJ, Torbicki A. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009 Jun 30; 54(1 Suppl 1):S55-66.
    View PubMed
  4. Hoeper MM, Barbera JA, Channick RN, Hassoun PM, Lang IM, Manes A, Martinez FJ, Naeije R, Olschewski H, Pepke-Zaba J, Redfield MM, Robbins IM, Souza R, Torbicki A, McGoon M. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol 2009 Jun 30; 54(1 Suppl 1):S85-96.
    View PubMed
  5. McGoon MD, Kane GC. Pulmonary hypertension: diagnosis and management. Mayo Clin Proc 2009 Feb; 84(2):191-207.
    View PubMed
  6. McGoon MD, Frost AE, Oudiz RJ, Badesch DB, Galie N, Olschewski H, McLaughlin VV, Gerber MJ, Dufton C, Despain DJ, Rubin LJ. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest 2009 Jan; 135(1):122-9. Epub 2008 Sep 23.
    View PubMed
  7. McGoon MD, Krichman A, Farber HW, Barst RJ, Raskob GE, Liou TG, Miller DP, Feldkircher K, Giles S. Design of the REVEAL registry for US patients with pulmonary arterial hypertension. Mayo Clin Proc 2008 Aug; 83(8):923-31.
    View PubMed
  8. McGoon MD, Krichman A, Farber HW, Barst RJ, Raskob GE, Liou TG, Miller DP, Feldkircher K, Giles S. Design of the REVEAL registry for US patients with pulmonary arterial hypertension. Mayo Clin Proc 2008 Aug; 83(8):923-31.
    View PubMed
  9. Frantz RP, Benza RL, Kjellstrom B, Bourge RC, Barst RJ, Bennett TD, McGoon MD. Continuous hemodynamic monitoring in patients with pulmonary arterial hypertension. J Heart Lung Transplant 2008 Jul; 27(7):780-8 Epub 2008 Jun 2.
    View PubMed
  10. Frantz RP, Benza RL, Kjellstrom B, Bourge RC, Barst RJ, Bennett TD, McGoon MD. Continuous hemodynamic monitoring in patients with pulmonary arterial hypertension. J Heart Lung Transplant 2008 Jul; 27(7):780-8. Epub 2008 Jun 02.
    View PubMed
  11. Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin LJ, Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind,, Placebo-Controlled, Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008 Jun 10; 117(23):3010-9. Epub 2008 May 27.
    View PubMed
  12. Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin LJ, Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind,, Placebo-Controlled, Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008 Jun 10; 117(23):3010-9. Epub 2008 May 27.
    View PubMed
  13. Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin LJ, Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008 Jun 10; 117(23):3010-9. Epub 2008 May 27.
    View PubMed
  14. Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin LJ. Ambrisentan for the treatment of pulmonary arterial hypertension - Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2. Circulation 2008 Jun 10; 117(23):3010-9.
    View PubMed
  15. Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin LJ, Ambrisentan in Pulmonary Arterial Hypertension Randomized Double-Blind Placebo-Controlled Multicent Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008 Jun 10; 117(23):3010-9 Epub 2008 May 27.
    View PubMed
  16. Karamanoglu M, McGoon M, Frantz RP, Benza RL, Bourge RC, Barst RJ, Kjellstrom B, Bennett TD. Right ventricular pressure waveform and wave reflection analysis in patients with pulmonary arterial hypertension. Chest 2007 Jul; 132(1):37-43. Epub 2007 May 15.
    View PubMed
  17. Puri A, McGoon MD, Kushwaha SS. Pulmonary arterial hypertension: current therapeutic strategies. Nat Clin Pract Cardiovasc Med 2007 Jun; 4(6):319-29.
    View PubMed
  18. Ryu JH, Krowka MJ, Pellikka PA, Swanson KL, McGoon MD. Pulmonary hypertension in patients with interstitial lung diseases. Mayo Clin Proc 2007 Mar; 82(3):342-50.
    View PubMed
  19. Shapiro BP, McGoon MD, Redfield MM. Unexplained pulmonary hypertension in elderly patients. Chest 2007 Jan; 131(1):94-100.
    View PubMed
  20. Barst R, Berman-Rosenzweig E, Horn E, Saiman L, Lee L, Southwick K, Kohlerschmidt D, Smith D, Gomberg-Maitland M, Weber S, Ivy D, McGoon M, Anderson Severson C, Rubenfire M, McLaughlin V, Feldman J, Tanner C, Chin K, Kingman M, Tapson V, Srinivasan A, Nob Bloodstream infections among patients treated with intravenous Epoprostenol or intravenous Treprostinil for pulmonary arterial hypertension --- seven sites, United States, 2003--2006. MMWR Morb Mortal Wkly Rep 2007; 56:170-2.
    View PubMed
  21. Krowka MJ, Swanson KL, Frantz RP, McGoon MD, Wiesner RH. Portopulmonary hypertension: Results from a 10-year screening algorithm. Hepatology 2006 Dec; 44(6):1502-10.
    View PubMed
  22. Voelkel NF, Quaife RA, Leinwand LA, Barst RJ, McGoon MD, Meldrum DR, Dupuis J, Long CS, Rubin LJ, Smart FW, Suzuki YJ, Gladwin M, Denholm EM, Gail DB, National Heart, Lung and Blood. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 2006 Oct 24; 114(17):1883-91.
    View PubMed
  23. Voelkel NF, Quaife RA, Leinwand LA, Barst RJ, McGoon MD, Meldrum DR, Dupuis J, Long CS, Rubin LJ, Smart FW, Suzuki YJ, Gladwin M, Denholm EM, Gail DB. Right ventricular function and failure - Report of a National Heart, lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 2006 Oct 24; 114(17):1883-91.
    View PubMed
  24. Voelkel NF, Quaife RA, Leinwand LA, Barst RJ, McGoon MD, Meldrum DR, Dupuis J, Long CS, Rubin LJ, Smart FW, Suzuki YJ, Gladwin M, Denholm EM, Gail DB, National Heart, Lung and Blood. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 2006 Oct 24; 114(17):1883-91.
    View PubMed
  25. Voelkel NF, Quaife RA, Leinwand LA, Barst RJ, McGoon MD, Meldrum DR, Dupuis J, Long CS, Rubin LJ, Smart FW, Suzuki YJ, Gladwin M, Denholm EM, Gail DB, National Heart, Lung and Blood. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 2006 Oct 24; 114(17):1883-91.
    View PubMed
  26. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation 2006 Sep 26; 114(13):1417-31.
    View PubMed
  27. Walker AM, Langleben D, Korelitz JJ, Rich S, Rubin LJ, Strom BL, Gonin R, Keast S, Badesch D, Barst RJ, Bourge RC, Channick R, Frost A, Gaine S, McGoon M, McLaughlin V, Murali S, Oudiz RJ, Robbins IM, Tapson V, Abenhaim L, Constantine G. Temporal trends and drug exposures in pulmonary hypertension: an American experience. Am Heart J 2006 Sep; 152(3):521-6.
    View PubMed
  28. Mahapatra S, Nishimura RA, Oh JK, McGoon MD. The prognostic value of pulmonary vascular capacitance determined by Doppler echocardiography in patients with pulmonary arterial hypertension. J Am Soc Echocardiogr 2006 Aug; 19(8):1045-50.
    View PubMed
  29. Elliott CG, Glissmeyer EW, Havlena GT, Carlquist J, McKinney JT, Rich S, McGoon MD, Scholand MB, Kim M, Jensen RL, Schmidt JW, Ward K. Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension. Circulation 2006 May 30; 113(21):2509-15. Epub 2006 May 22.
    View PubMed
  30. Mahapatra S, Nishimura RA, Sorajja P, Cha S, McGoon MD. Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension. J Am Coll Cardiol 2006 Feb 21; 47(4):799-803. Epub 2006 Jan 26.
    View PubMed
  31. Urheim S, Cauduro S, Frantz R, McGoon M, Belohlavek M, Green T, Miller F, Bailey K, Seward J, Tajik J, Abraham TP. Relation of tissue displacement and strain to invasively determined right ventricular stroke volume. Am J Cardiol 2005 Oct 15; 96(8):1173-8.
    View PubMed
  32. Mahapatra S, Bybee KA, Bunch TJ, Espinosa RE, Sinak LJ, McGoon MD, Hayes DL. Incidence and predictors of cardiac perforation after permanent pacemaker placement. Heart Rhythm 2005 Sep; 2(9):907-11.
    View PubMed
  33. Galie N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, Frost AE, Zwicke D, Naeije R, Shapiro S, Olschewski H, Rubin LJ. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005 Aug 2; 46(3):529-35.
    View PubMed
  34. Ramakrishna G, Sprung J, Ravi BS, Chandrasekaran K, McGoon MD. Impact of pulmonary hypertension on the outcomes of noncardiac surgery: predictors of perioperative morbidity and mortality. J Am Coll Cardiol 2005 May 17; 45(10):1691-9.
    View PubMed
  35. McGoon M, Gutterman D, Steen V, Barst R, McCrory DC, Fortin TA, Loyd JE. Screening, early detection, and diagnosis of pulmonary arterial hypertension - ACCP evidence-based clinical practice guidelines. Chest 2004 Jul; 126(1 Suppl S):14S-34S.
    View PubMed
  36. Newman JH, Fanburg BL, Archer SL, Badesch DB, Barst RJ, Garcia JGN, Kao PN, Knowles JA, Loyd JE, McGoon MD, Morse JH, Nichols WC, Rabinovitch M, Rodman DM, Stevens T, Tuder RM, Voelkel NF, Gail DB. Pulmonary arterial hypertension - Future directions - Report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshop. Circulation 2004 Jun 22; 109(24):2947-52.
    View PubMed
  37. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, Gaine S. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004 Jun 16; 43(12 Suppl S):40S-47S.
    View PubMed
  38. Rubin L, Galie N, Badesch DB, Oudiz R, Simonneau G, McGoon MD, Manes A, Keogh A, Frost A, Zwicke D, Naeije R. Ambrisentan improves exercise capacity, clinical measures in pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169(7):A210.
    View PubMed
  39. Bhatia S, Frantz RP, Severson CJ, Durst LA, McGoon MD. Immediate and long-term hemodynamic and clinical effects of Sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. Mayo Clin Proc 2003 Oct; 78(10):1207-13.
    View PubMed
  40. Bhatia S, Morrison JF, Bower TC, McGoon MD. Pulmonary hypertension in the setting of acquired systemic arteriovenous fistulas. Mayo Clin Proc 2003 Jul; 78(7):908-12.
    View PubMed
  41. Barst RJ, McGoon M, McLaughlin V, Tapson V, Oudiz R, Shapiro S, Robbins IM, Channick R, Badesch D, Rayburn BK, Flinchbaugh R, Sigman J, Arneson C, Jeffs R. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003 Jun 18; 41(12):2119-25.
    View PubMed
  42. McLaughlin VV, Gaine SP, Barst RJ, Oudiz RJ, Bourge RC, Frost A, Robbins IM, Tapson VF, McGoon MD, Badesch DB, Sigman J, Roscigno R, Blackburn SD, Arneson C, Rubin LJ, Rich S. Efficacy and safety of treprostinil: An Epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 2003 Feb; 41(2):293-9.
    View PubMed
  43. Frantz RP, McGoon MD, Severson C, Tointon S, Ballman K, Bailey KR, Heublein D, Burnett JC. Neurohumoral profiles in pulmonary hypertension: clinical and hemodynamic relationships. 5th International Congress on Lung Transplantation, Paris France, September 19-20, 2002.
  44. Langleben D, Christman BW, Barst RJ, Dias VC, Galie N, Higenbottam TW, Kneussl M, Korducki L, Naeije R, Riedel A, Simonneau G, Hirsch AM, Rich S, Robbins IM, Oudiz R, McGoon MD, Badesch DB, Levy RD, Mehta S, Seeger W, Soler M. Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. Am Heart J 2002 May; 143(5):E4.
    View PubMed
  45. Kelly AM, Porter CJ, McGoon MD, Espinosa RE, Osborn MJ, Hayes DL. Breath-holding spells associated with significant bradycardia: successful treatment with permanent pacemaker implantation. Pediatrics 2001 Sep; 108(3):698-702.
    View PubMed
  46. McGoon MD. The assessment of pulmonary hypertension. Clin Chest Med 2001 Sep; 22(3):493-508.
    View PubMed
  47. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM, Jobsis MM, Loyd JE, Murali S, Frost A, Girgis R, Bourge RC, Ralph DD, Elliott CG, Hill NS, Langleben D, Schilz RJ, McLaughlin VV, Robbins IM, Groves Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000 Mar 21; 132(6):425-34.
    View PubMed
  48. Connolly HM, McGoon MD. Obesity drugs and the heart. Curr Probl Cardiol 1999 Dec; 24(12):749-92.
    View PubMed
  49. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999 Sep; 30(3):641-8.
    View PubMed
  50. Kopecky SL, Gersh BJ, McGoon MD, Chu CP, Ilstrup DM, Chesebro JH, Whisnant JP. Lone atrial fibrillation in elderly persons: a marker for cardiovascular risk. Arch Intern Med 1999 May 24; 159(10):1118-22.
    View PubMed
  51. Castro PF, Bourge RC, McGiffin DC, Benza RL, Fan P, Pinkard NB, McGoon MD. Intrapulmonary shunting in primary pulmonary hypertension: an observation in two patients treated with epoprostenol sodium. Chest 1998 Jul; 114(1):334-6.
    View PubMed
  52. Yeo TC, Dujardin KS, Tei C, Mahoney DW, McGoon MD, Seward JB. Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am J Cardiol 1998 May 1; 81(9):1157-61.
    View PubMed
  53. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997 Aug 28; 337(9):581-8.
    View PubMed
  54. Hinderliter AL, Willis PW, Barst RJ, Rich S, Rubin LJ, Badesch DB, Groves BM, Mcgoon MD, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Koch G, Li S, Clayton LM, Jobsis MM, Blackburn SD, Crow JW, Long WA. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Circulation 1997 Mar 18; 95(6):1479-1486.
    View PubMed
  55. McGoon MD. Prognosis and natural history. Lung Biol Health Dis 1997; 99:305-317.
  56. Tei C, Dujardin KS, Hodge DO, Bailey KR, McGoon MD, Tajik AJ, Seward SB. Doppler echocardiographic index for assessment of global right ventricular function. J Am Soc Echocardiogr 1996 Nov-Dec; 9(6):838-47.
    View PubMed
  57. Lloyd MA, Hayes DL, Holmes DR Jr, Stanson AW, Espinosa RE, Osborn MJ, McGoon MD. Extraction of the Telectronics Accufix 330-801 atrial lead: the Mayo Clinic experience. Mayo Clin Proc 1996 Mar; 71(3):230-4.
    View PubMed
  58. Barst RJ, Rubin LJ, Long WA, Mcgoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, Jobsis MM, Blackburn SD, Shortino D, Crow JW. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996 Feb 1; 334(5):296-301.
    View PubMed
  59. Cannan CR, McGoon MD, Holmes DR Jr, Lerman A. Altered coronary endothelial function in a patient with asymptomatic left ventricular dysfunction. Int J Cardiol 1996 Feb; 53(2):147-51.
    View PubMed
  60. Abenheim L, Moride Y, Brenot F, McGoon MD, et al for the international Primary Pulmonary Hypertension Study Group. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Eng J Med 1996; 335:609-16.
  61. McGoon MD. Medical treatment of pulmonary hypertension. Cardiologia 1995 Aug; 40(8):561-77.
    View PubMed
  62. Sueta CA, Gheorghiade M, Adams KF, Bourge RC, Murali S, Uretsky BF, Pritzker MR, McGoon MD, Butman SM, Grossman SH, Crow JW, Shaffer CL, Thorn MD. Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Am J Cardiol 1995 Jan 19; 75:A34-A43.
  63. Enriquez-Sarano M, Tajik AJ, Schaff HV, Orszulak TA, McGoon MD, Bailey KR, Frye RL. Echocardiographic prediction of left ventricular function after correction of mitral regurgitation: results and clinical implications. J Am Coll Cardiol 1994 Nov 15; 24(6):1536-43.
    View PubMed
  64. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994 Sep 15; 121(6):409-15.
    View PubMed
  65. Porter CJ, McGoon MD, Espinosa RE, Osborn MJ, Hayes DL. Apparent breath-holding spells associated with life-threatening bradycardia treated by permanent pacing. Ped Cardiol 1994; 15:260.
  66. Espinosa RE, Hayes DL, Vlietstra RE, Osborn MJ, McGoon MD. The Dotter retriever and pigtail catheter: efficacy in extraction of chronic transvenous pacemaker leads. Pacing & Clinical Electrophysiology 1993 Dec; 16(12):2337-42.
    View PubMed
  67. Murphy JG, Gersh BJ, Mair DD, Fuster V, McGoon MD, Ilstrup DM, McGoon DC, Kirklin JW, Danielson GK. Long-term outcome in patients undergoing surgical repair of tetralogy of Fallot. N Engl J Med 1993 Aug 26; 329(9):593-9.
    View PubMed
  68. Rubin LJ, Barst RJ, Kaiser LR, Koerner SK, Loyd JE, McGoon MD, Pietra G, Rich S, Rubenfire M, Theodore J. Primary pulmonary hypertension. Chest 1993; 104:236-50.
    View PubMed
  69. McGoon MD, Frantz RP. Techniques of immunosuppression after cardiac transplantation. Mayo Clin Proc 1992 Jun; 67:586-595.
    View PubMed
  70. Porter CB, Fukushige J, Hayes DL, McGoon MD, Osborn MJ, Puga FJ. Permanent antitachycardia pacing for chronic atrial tachyarrhythmias in postoperative pediatric patients. Pacing Clin Electrophysiol 1991 Nov; 14(11 Pt 2):2056-7.
    View PubMed
  71. Iqbal A, Gibbons RJ, McGoon MD, Steiroff S, Frohnert PT, Velosa JA. Noninvasive assessment of cardiac risk in insulin-dependent diabetic patients being evaluated for pancreatic transplantation using thallium-201 myocardial perfusion scintigraphy. Transplant Proc 1991 Feb; 23(1 Pt 2):1690-1.
    View PubMed
  72. Fukushige J, Porter CJ, Hayes DL, McGoon MD, Osborn MJ, Vlietstra RE. Antitachycardia pacemaker treatment of postoperative arrhythmias in pediatric patients. PACE 1991; 14:546-56.
    View PubMed
  73. Murphy JG, Gersh BJ, McGoon MD, Mair DD, Porter C-BJ, Ilstrup DM, McGoon DC, Puga FJ, Kirklin JW, Danielson GK. Long-term outcome after surgical repair of isolated atrial septal defect. N Engl J Med 1990 Dec 13; 323:1645-1650.
    View PubMed
  74. Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, Diehl JH, Crow J, Long W. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990 Apr 1; 112(7):485-91.
    View PubMed
  75. Murphy J, Gersh B, McGoon M, Mair D, Porter C, Ilstrup D, McGoon D, Kirklin J, Danielson G. The natural history of surgically repaired atrial septal defect: follow-up at 30 years. New England Journal of Medicine 1990; 323:1645-50.
    View PubMed
  76. McGoon MD, Shapland JE, Salo R, Pederson B, Olive A. The feasibility of utilizing the systolic pre-ejection interval as a determinant of pacing rate. J Am Coll Cardiol 1989 Dec; 14(7):1753-8.
    View PubMed
  77. Redfield MM, Edwards BS, McGoon MD, Heublein DM, Aarhus LL, Burnett JC Jr. Failure of atrial natriuretic factor to increase with volume expansion in acute and chronic congestive heart failure in the dog. Circulation 1989 Sep; 80(3):651-7.
    View PubMed
  78. McGoon MD. Rate-responsive pacing using an impedance lead. J Electrocardiol 1989; 22(Suppl):223.
    View PubMed
  79. Kopecky SL, Gersh BJ, McGoon MD, Mair DD, Porter CJ, Ilstrup DM, McGoon DC, Kirklin JW, Danielson GK. Long-term outcome of patients undergoing surgical repair of isolated pulmonary valve stenosis. Follow-up at 20-30 years. Circulation 1988 Nov; 78(5 Pt 1):1150-6.
    View PubMed
  80. Nishimura RA, McGoon MD, Schaff HV, Giuliani ER. Chronic aortic regurgitation: indications for operation--1988. Mayo Clin Proc 1988 Mar; 63(3):270-80.
    View PubMed
  81. Horowitz SF, Matza D, Machac J, Alexopoulos D, McGoon MD, Gibbons RJ, Fuster V. Right and left ventricular functional response to supine exercise in patients with asymptomatic mitral regurgitation. J Am Coll Cardiol 1988 Feb; 11(Suppl A):229A.
  82. Kopecky S, Gersh BJ, McGoon MD, Mair D, Porter CJ, Ilstrup D, McGoon DC, Kirklin J, Danielson GK. Long-term prognosis for patients undergoing surgical repair of isolated pulmonary valve stenosis: follow-up at 20 to 30 yrs. Circulation 1988; 78:1150-6.
    View PubMed
  83. McGoon MD, Fetter J. Noninvasive conversion of a fixed-rate demand pacemaker to activity mode: a method for assessing the clinical effect of rate-responsiveness. Mayo Clin Proc 1987 Oct; 62(10):882-5.
    View PubMed
  84. Kopecky SL, Gersh BJ, McGoon MD, Whisnant JP, Holmes DR, Ilstrup DM, Frye RL. The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med 1987 Sep 10; 317(11):669-74.
    View PubMed
  85. McGoon MD, Vlietstra RE. Acute hemodynamic response to the S2-serotonergic receptor antagonist, ketanserin, in patients with primary pulmonary hypertension. Int J Cardiol 1987 Mar; 14(3):303-9.
    View PubMed
  86. Kopecky SL, Gersh BJ, McGoon MD, Whisnant JP, Holmes DR, Ilstrup DM, Frye, Rl. Lone atrial fibrillation in patients less than 60 years old - a three decade population based study. N Engl J Med 1987; 317:669-74.
    View PubMed
  87. Mills TJ, Seward JB, McGoon MD, Callahan MJ. Platypnea-orthodeoxia: assessment with a unique cardiac catheterization procedure. Cathet Cardiovasc Diagn 1986; 12(2):100-2.
    View PubMed
  88. Talierco CP, McGoon MD, Vlietstra RE, Porter C-BJ, Osborn MJ, Danielson GK. Cardiac pacing after the Fontan procedure: 1973-1986. Clin Prog Electrophysiol Pacing 1986; 4:246.
  89. McGoon MD, Callahan MJ, Gersh BJ. Optimal timing of valvular surgery. Appl Cardiol 1986; 14:19-24.
  90. Nishimura RA, McGoon MD, Shub C, Miller FA Jr, Ilstrup DM, Tajik AJ. Echocardiographically documented mitral-valve prolapse. Long-term follow-up of 237 patients. N Engl J Med 1985 Nov 21; 313(21):1305-9.
    View PubMed
  91. Taliercio CP, Vlietstra RE, McGoon MD, Porter CJ, Osborn MJ, Danielson GK. Permanent cardiac pacing after the Fontan procedure. J Thorac Cardiovasc Surg 1985 Sep; 90(3):414-9.
    View PubMed
  92. Shub C, Vlietstra RE, McGoon MD. Selection of optimal drug therapy for the patient with angina pectoris. Mayo Clin Proc 1985 Aug; 60(8):539-48.
    View PubMed
  93. Lemery R, McGoon MD, Edwards WD. Cardiac sarcoidosis: a potentially treatable form of myocarditis. Mayo Clin Proc 1985 Aug; 60(8):549-54.
    View PubMed
  94. McGoon MD, Edwards WD. Primary pulmonary hypertension: current status. Mod Concepts Cardiovasc Dis 1985 Jun; 54:29-33.
  95. McGoon MD, Vlietstra RE. Vasodilator therapy for primary pulmonary hypertension. Mayo Clin Proc 1984 Oct; 59(10):672-7.
    View PubMed
  96. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984 Oct; 70(4):580-7.
    View PubMed
  97. Vlietstra RE, McGoon MD. Beta-adrenergic blockers. Choosing among them. Postgrad Med 1984 Sep 1; 76:70-80.
    View PubMed
  98. McGoon MD, Vanhoutte PM. Aggregating platelets contract isolated canine pulmonary arteries by releasing 5-hydroxytryptamine. J Clin Invest 1984 Sep; 74(3):828-33.
    View PubMed
  99. Sugrue DD, Wood DL, McGoon MD. Carotid sinus hypersensitivity and syncope. Mayo Clin Proc 1984 Sep; 59(9):637-40.
    View PubMed
  100. McGoon MD, Fuster V, McGoon DC, Pumphrey CW, Pluth JR, Elveback LR. Aortic and mitral valve incompetence: long-term follow-up (10 to 19 years) of patients treated with the Starr-Edwards prosthesis. J Am Coll Cardiol 1984 Apr; 3(4):930-8.
    View PubMed
  101. Nishimura RA, McGoon MD, Shub C, Ilstrup DM, Tajik AJ. Long-term follow-up of mitral valve prolapse documented by M-mode echocardiography in 283 patients. Circulation 1984; 70.
  102. McGoon MD, Seward JB, Vlietstra RE, Choo MH, Moyer TP, Reeder GS. Haemodynamic response to intravenous hydralazine in patients with pulmonary hypertension. Br Heart J 1983 Dec; 50(6):579-85.
    View PubMed
  103. Fuster V, Pumphrey CW, McGoon MD, Chesebro JH, Pluth JR, McGoon DC. Systemic thromboembolism in mitral and aortic Starr-Edwards prostheses: a 10-19 year follow-up. Circulation 1982 Aug; 66(PART II):157-161.
  104. McGoon MD, Vlietstra RE, Holmes DR, Osborn JE. The clinical use of verapamil. Mayo Clin Proc 1982 Aug; 57(8):495-510.
    View PubMed
  105. McGoon MD, Maloney JD, McGoon DC, Danielson GK. Long-term endocardial atrial pacing in children with postoperative bradycardia-tachycardia syndrome and limited ventricular access. Am J Cardiol 1982 May; 49(7):1750-7.
    View PubMed
  106. McGoon MD, Maloney JD, McGoon DC, Danielson GK. Chronic endocardial atrial pacing in children with postoperative bradycardia-tachycardia syndrome and limited ventricular access. Am J Cardiol 1982; 49:1750-7.
    View PubMed
  107. Bo-Linn GW, Anderson DJ, Anderson KC, McGoon MD. Percutaneous central venous catheterization performed by medical house officers: a prospective study. Cathet Cardiovasc Diagn 1982; 8(1):23-9.
    View PubMed
  108. McGoon MD, Benedetto PW, Greene BM. Complications of percutaneous central venous catheterization: a report of two cases and review of the literature. Johns Hopkins Med J 1979 Jul; 145(1):1-6.
    View PubMed
  109. McGoon MD, Fulton RE, Davis GD, Ritter DG, Neill CA, White RI Jr. Systemic collateral and pulmonary artery stenosis in patients with congenital pulmonary valve atresia and ventricular septal defect. Circulation 1977 Sep; 56(3):473-9.
    View PubMed


Appointments Contact Us Make A Gift Search

Legal restrictions and terms of use applicable to this site

Use of this site signifies your agreement to the terms of use
Copyright © 2009 Mayo Foundation for Medical Education and Research.